Trial · NCT02704598
Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.
NCT02704598, Not applicable, Unknown, Hospital do Servidor Publico Estadual
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs. Trials, record NCT02704598. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02704598
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.
- NCT number
- NCT02704598
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 84 participants, estimated
- Lead sponsor
- Hospital do Servidor Publico Estadual
- Conditions
- Deep Venous Thrombosis
- Interventions
- Rivaroxaban, Warfarin
- First posted
- 2016-03-10
- Last updated
- 2018-10-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the long-term outcomes (after 12 months) in two groups of patients after treatment for DVT, by comparing the DUS-detected recanalization rates and the occurrence of PTS. | 6 months after the diagnosis of deep venous thrombosis. | The patients are evaluated within 6 months with Duplex ultrasound to assess the recanalization rate. The criteria to assess Deep venous thrombosis are defined as as visualization of thrombus and/or lack of complete compressibility of the vein. Thrombus involving popliteal and/or more proximal veins was classified as proximal Deep venous thrombosis (DVT). The US findings in DVT include: the presence of echoes within the vascular lumen; the veins in axial scans are not compressible. Pulsed Doppler and duplex Doppler combine the morphologic and functional study. Injury caused by DVT at the valvular level (postphlebitic syndrome) is visualized. Venous segments were examined whether they were occluded, partially recanalized, or totally recanalized, and the development of venous reflux was evaluated. |
| Secondary | Clinical Signs and Symptoms in 84 patients.. | 6 months the diagnosis of deep venous thrombosis. | The patients are evaluated within 6 months with clinical examination, to evaluate presence of pain in lower limbs, swelling and varicose veins. The post-thrombotic syndrome is characterized by aching pain on standing, dependent oedema, and the frequent develop-ment of brawny, tender induration of the subcutaneous tissues of the medial lower limb, a condition that has been termed lipodermatosclerosis. Pruritus and eczematous skin changes are frequently present, and a proportion of patients develop secondary superficial varicose veins as the syndrome evolves.Ulceration, often precipitated by minor trauma, arises in a considerable number of patients and is characteristically chronic and indolent with a high recurrence rate, once healing has been achieved. Uncommonly, patients with persistent obstruction may experience venous claudication, a bursting pain in the leg during exercise, which, in some respects,mimics arterial claudication (Immelman \& Jeffrey, 1984). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02704598
GET https://conductscience.org/api/trials/v1/NCT02704598/registered